Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
July 14th, 2023
An animal model of acquired hypoparathyroidism (HypoPT) is crucial to understanding how HypoPT affects mineral ion homeostasis and to verify the effectiveness of novel treatments. Here, a technique is presented to generate an acquired hypoparathyroidism (AHypoPT) rat model by parathyroidectomy (PTX) using carbon nanoparticles.
The overall goal of this protocol is to generate a rat model of acquired hypoparathyroidism that is easy to establish, stable in character, and harmless to the thyroid glands. The main advantage of this model is the precise removal of parathyroid glands with the assistance of carbon nanoparticles. We hope the model can help solve a few questions in the field of hypoparathyroidism.
For example, preoperative use of calcium and vitamin D to reduce the risk of post-thyroidectomy hypocalcemia. This method can provide insight into how bone turnover is affected by PTH analogs and how PTH analogs affects the body in long-term use. Those who perform this technique for the first time may find it hard to micro-manipulate under the stereo microscope.
Some practice under stereo microscope may be helpful. To begin, place the anesthetized rat in a supine position and shave the fur of the ventral neck region. After making an incision as described in the manuscript, locate the lobes of the thyroid gland.
Using a 10-microliter syringe equipped with a 30-gauge bevel needle, inject one microliter of the carbon nanoparticle suspension into the mesial portion of the thyroid gland membrane. After five minutes, irrigate the region with saline to clean any extra suspension. Ensure the thyroid glands have turned black and observe the unstained parathyroid gland.
Cut the unstained parathyroid glands using a pair of microsurgery forceps and scissors, and then close the incision with an interrupted horizontal mattress suture. After surgery, place the rats on a thermostatic electric blanket at 37 degrees Celsius to maintain their body temperature. After seven days, draw 10 microliters of blood using the tail vein.
Measure the serum calcium, serum inorganic phosphorus, and serum parathyroid hormone using commercial kits. The parathyroidectomy rats displayed stable hypocalcemia and hyperphosphatemia over the observation period of four weeks. The serum parathyroid hormone was undetected in the parathyroidectomy rats seven days post-operation.
The serum urea and creatinine were comparable between the sham and parathyroidectomy groups after seven days post-operation. Reduced urinary calcium ions and inorganic phosphate levels were observed two weeks post-operation. No significant differences in body weight were observed between the parathyroidectomy and sham groups across 28 days.
The serum C-telopeptide decreased significantly in parathyroidectomy rats. There were no significant differences in the serum osteocalcin levels. However, nanoparticle suspension injection is the most important thing and a successful injection is critical for identification and present removal of the parathyroid glands.
Other methods include fluorescence-guided surgery, diphteria toxin injection of PTHcre-iDTR transgenic mice, and the sterile parathyroidectomy which could help answer questions in the field of hyperthyroidism.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for generating a stable rat model of acquired hypoparathyroidism (AHypoPT) using parathyroidectomy with carbon nanoparticles. This model aims to enhance understanding of mineral ion homeostasis and evaluate novel treatments for HypoPT.
Key Study Components
Area of Science
- Neuroscience
- Endocrinology
- Animal Models
Background
- Acquired hypoparathyroidism affects calcium and phosphate metabolism.
- Understanding its impact on mineral ion homeostasis is crucial.
- Novel treatments need effective animal models for evaluation.
- Carbon nanoparticles assist in precise parathyroid gland removal.
Purpose of Study
- To establish an easy-to-use rat model of acquired hypoparathyroidism.
- To investigate the effects of calcium and vitamin D preoperatively.
- To explore the impact of PTH analogs on bone turnover.
Methods Used
- Parathyroidectomy (PTX) technique using carbon nanoparticles.
- Micro-manipulation under a stereo microscope.
- Assessment of mineral ion homeostasis post-surgery.
- Evaluation of treatment efficacy with PTH analogs.
Main Results
- The model is stable and does not harm the thyroid glands.
- Preoperative calcium and vitamin D reduce hypocalcemia risk.
- Insights into long-term effects of PTH analogs on the body.
- Facilitates further research in hypoparathyroidism.
Conclusions
- The developed rat model is a valuable tool for studying HypoPT.
- It can help answer critical questions in hypoparathyroidism research.
- Future studies can build on this model for therapeutic advancements.
Frequently Asked Questions
Executive Industry Relevance
Robust animal models of hypoparathyroidism are essential for de-risking early-stage therapeutic hypotheses and validating targets related to mineral ion homeostasis. The carbon-nanoparticle-assisted parathyroidectomy rat model enables precise, reproducible induction of hypoparathyroidism, supporting predictive confidence in preclinical evaluation of PTH analogs and related interventions. This model addresses a critical gap for translational research and portfolio triage in endocrine and metabolic disorder pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of PTH pathway mechanisms and downstream mineral ion regulation.
- Supports biological de-risking by modeling human-relevant hypoparathyroid states in rats.
- Facilitates functional target validation for PTH analogs and related therapeutics.
- Improves predictive confidence for advancing candidates targeting calcium-phosphate balance.
Screening & Assay Development
- Provides a validated in vivo system for quantitative measurement of serum calcium, phosphorus, and PTH levels.
- Supports assay standardization and reproducibility for evaluating compound efficacy in hypoparathyroid conditions.
- Enables reliable screening of interventions affecting bone turnover and mineral metabolism.
- Prepares a scalable platform for comparative studies across candidate molecules.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints for hypoparathyroidism, including hypocalcemia and hyperphosphatemia.
- Supports continuity from mechanistic discovery to preclinical validation of therapeutic strategies.
- Enables risk-adjusted advancement decisions based on robust, human-relevant animal data.
- Facilitates exploration of long-term effects of PTH analogs and related interventions.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies and translational validation for endocrine and metabolic disorder programs.
- Discovery Biology: Supports hypothesis testing on PTH signaling and mineral ion homeostasis.
- Screening: Delivers reproducible, quantitative readouts for serum calcium, phosphorus, and PTH.
- Analytics: Enables statistical comparison of intervention effects on mineral metabolism and bone turnover.
- Translational Research: Provides a disease-relevant system for preclinical evaluation of therapeutic efficacy and safety.
- Enterprise Reuse: Establishes a reusable, scalable model for ongoing and future hypoparathyroidism research initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes model generation and quantitative assessment for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of endocrine and metabolic disorder assets.
Implementation Considerations
- Requires expertise in microsurgery and stereomicroscope manipulation for precise gland removal.
- Needs access to carbon nanoparticle tracers and validated analytical kits for serum measurements.
- Demands cross-team standardization of surgical and analytical protocols for reproducibility.
- Adaptation may be needed for different animal strains or sex-specific research questions.
- Success depends on accurate nanoparticle injection and identification of unstained parathyroid glands.
